Laboratory Test Predictors for Major Bleeding in Elderly (≥80 Years) Patients With Nonvalvular Atrial Fibrillation Treated With Edoxaban 15 mg: Sub‐Analysis of the ELDERCARE‐AF Trial
Background We investigated the predictors related to major bleeding events during treatment with edoxaban 15 mg in patients aged ≥80 years with nonvalvular atrial fibrillation and high bleeding risk, for whom standard oral anticoagulants are inappropriate, focusing on standard laboratory tests relat...
Main Authors: | Takeshi Mikami, Kagami Hirabayashi, Keisuke Okawa, Tetsuo Betsuyaku, Saori Watanabe, Yuki Imamura, Kimihiko Tanizawa, Takuya Hayashi, Masaharu Akao, Takeshi Yamashita, Ken Okumura |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-09-01
|
Series: | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
Subjects: | |
Online Access: | https://www.ahajournals.org/doi/10.1161/JAHA.122.024970 |
Similar Items
-
Efficacy and Safety of Low‐Dose Edoxaban by Body Weight in Very Elderly Patients With Atrial Fibrillation: A Subanalysis of the Randomized ELDERCARE‐AF Trial
by: Masaharu Akao, et al.
Published: (2024-02-01) -
Efficacy and Safety of Renal Function on Edoxaban Versus Warfarin for Atrial Fibrillation: A Systematic Review and Meta-Analysis
by: Yapeng Wang, et al.
Published: (2023-01-01) -
Postmarketing surveillance on the clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA‐AF‐Japan): One‐year safety and effectiveness analyses
by: Takeshi Yamashita, et al.
Published: (2020-06-01) -
Postmarketing surveillance on clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA‐AF‐Japan): Three‐month interim analysis results
by: Takeshi Yamashita, et al.
Published: (2019-02-01) -
Safety and effectiveness of edoxaban in Japanese patients with nonvalvular atrial fibrillation: Final report of a two‐year postmarketing surveillance study (ETNA‐AF‐Japan)
by: Takeshi Yamashita, et al.
Published: (2021-04-01)